A Study of Certolizumab Pegol as Additional Therapy in Chinese Patients With Active Rheumatoid Arthritis
Clinical trial NCT02151851 · COMPLETED
Trial details
- NCT number
- NCT02151851
- Sponsor
- UCB Pharma SA, Belgium
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2014-07-01
- Primary completion
- 2016-06-01
- Enrollment
- 430
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.